In addition, our results highlight that polyvascular disease is an important independent indicator of HHF risk, raising the hypothesis that SGLT2 inhibitors may have therapeutic potential in such patients, irrespective of their T2DM or prior HF status. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.